Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 308 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Locations: - Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
- Arizona Center for Cancer Care-Peoria — Peoria, Arizona
- Arizona Center for Cancer Care - Biltmore — Phoenix, Arizona
+ 197 more sites in the U.S.
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
+ 103 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Locations: - Ironwood Cancer and Research Center — Chandler, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
- Providence St Jude Medical Center — Fullerton, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Locations: - Site 164 — Mobile, Alabama
- Site 36 — La Jolla, California
- Site 27 — Los Angeles, California
+ 34 more sites in the U.S.
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Locations: - Research Site — Birmingham, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
+ 25 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- University of California Los Angeles — Los Angeles, California
+ 25 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Locations: - Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
- Mount Sinai Braman Comprehensive Cancer Center ( Site 5043) — Miami Beach, Florida
- Mount Sinai Comprehensive Cancer Center ( Site 6000) — Miami Beach, Florida
+ 16 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …
Sponsor: BioNTech SE
NCT ID: NCT04534205
Locations: - California Research Institute — Los Angeles, California
- UCLA Cancer Care — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Locations: - Helios CR Inc./RadNet — Cerritos, California
- City of Hope National Cancer Center — Duarte, California
- Hoag Memorial Hospital — Irvine, California
+ 12 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…
Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Locations: - City of Hope — Duarte, California
- University of Miami — Miami, Florida
- Tampa General Hospital — Tampa, Florida
+ 5 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…
Sponsor: Privo Technologies
NCT ID: NCT05893888
Locations: - City of Hope National Medical Center — Duarte, California
- Miami Cancer Institute — Miami, Florida
- The University of Chicago — Chicago, Illinois
+ 1 more site in the U.S.